Cargando…

Advances in Multiple Sclerosis 2017

Detalles Bibliográficos
Autores principales:	Göbel, Kerstin, Kleinschnitz, Christoph, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877762/ https://www.ncbi.nlm.nih.gov/pubmed/29562661 http://dx.doi.org/10.3390/ijms19030901

Ejemplares similares

Glatiramer acetate does not protect from acute ischemic stroke in mice
por: Kraft, Peter, et al.
Publicado: (2014)

Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review
por: Dreikorn, Mirjam, et al.
Publicado: (2018)

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders—A Systematic Review
por: Göbel, Kerstin, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone
por: Krämer, Julia, et al.
Publicado: (2021)

Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation
por: Albert-Weissenberger, Christiane, et al.
Publicado: (2012)

The Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders
por: Pankratz, Susann, et al.
Publicado: (2016)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Report on the 7th scientific meeting of the Association for the Advancement of Young Academics in Neurology (NEUROWIND e.V.) held in Motzen, Germany, October 30–November 1, 2015
por: Korn, Thomas, et al.
Publicado: (2016)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Advances in Multiple Sclerosis Research–Series I
por: Apostolopoulos, Vasso, et al.
Publicado: (2020)

Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis
por: Doerck, Sebastian, et al.
Publicado: (2010)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment
por: Duarte-Silva, Eduardo, et al.
Publicado: (2022)

The role of iron metabolism in the pathogenesis and treatment of multiple sclerosis
por: Duarte-Silva, Eduardo, et al.
Publicado: (2023)

Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis
por: Vogelsang, Anna, et al.
Publicado: (2021)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Early and Degressive Putamen Atrophy in Multiple Sclerosis
por: Krämer, Julia, et al.
Publicado: (2015)

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
por: Brummer, Tobias, et al.
Publicado: (2021)

Report on the 1st scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Mittenwalde/Motzen, Germany, Oct. 30th - Nov. 1st, 2009
por: Magnus, Tim, et al.
Publicado: (2010)

Infectious mononucleosis is associated with an increased incidence of multiple sclerosis: Results from a cohort study of 32,116 outpatients in Germany
por: Loosen, Sven H., et al.
Publicado: (2022)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis
por: Duarte-Silva, Eduardo, et al.
Publicado: (2022)

Report on the 3'rd scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Nov. 4'th - Nov. 6'th, 2011
por: Kleinschnitz, Christoph, et al.
Publicado: (2012)

Report on the 2nd scientific meeting of the "Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie" (NEUROWIND e.V.) held in Motzen, Germany, Oct. 29'th - Oct. 31'st, 2010
por: Magnus, Tim, et al.
Publicado: (2011)

Report on the 5‘th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Oct. 25th – Oct. 27th, 2013
por: Linker, Ralf A, et al.
Publicado: (2013)

Report on the 4'th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Nov. 2’nd – Nov. 4’th, 2012
por: Linker, Ralf A, et al.
Publicado: (2012)

Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model
por: Schuhmann, Michael K., et al.
Publicado: (2015)

Report on the 6th scientific meeting of the “Verein zur Förderung des Wissenschaftlichen Nachwuchses in der Neurologie” (NEUROWIND e.V.) held in Motzen, Germany, Oct. 31th – Nov. 2nd, 2014
por: Kleinschnitz, Christoph, et al.
Publicado: (2015)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Multiple Sclerosis
por: Ramagopalan, Sreeram, et al.
Publicado: (2011)

Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease
por: Dimitriou, Nikolaos G., et al.
Publicado: (2023)

The NKG2D – IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies
por: Ruck, Tobias, et al.
Publicado: (2015)

Multiple Sclerosis in India
por: Goyal, Vinay
Publicado: (2018)

Multiples sclerosis in India
por: Khadilkar, Satish V.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f3eto3na22rodbucog7l39aho4